Arrowhead Banks on S-antigen Level Cuts with HBV Drug, IDs Next Clinical Candidate | GenomeWeb

NEW YORK (GenomeWeb) – As it presses ahead with Phase II development of its flagship hepatitis B therapy ARC-520, Arrowhead Research is banking on the drug's ability to cut levels of the virus's surface antigen (s-antigen), a key indicator of active infection, the company's top executive said this week.

According to Arrowhead President and CEO Chris Anzalone, treating HBV has proven especially challenging because blocking viral replication alone is not enough to clear the virus, unlike with hepatitis C.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: genomic analysis of 200 bird species, and more.

The Australian High Court rules that isolated genetic material cannot be patented.

The startup incubator Y Combinator is launching a nonprofit research lab.

In Genome Research this week: vervet genome, tandem repeats affect gene expression in great apes, and more.